Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
Status:
Completed
Trial end date:
2021-08-20
Target enrollment:
Participant gender:
Summary
The purpose of this phase I/Ib study is to determine the safety profile of Epidiolex (CBD
oil) in biochemically recurrent prostate cancer patients. The study consists of a dose
escalation part and dose expansion part. The dose expansion part of the study will use the
maximum tolerated dose (MTD) determined in the dose escalation part to assess the activity,
safety and tolerability of the investigational product in patients with biochemically
recurrent prostate cancer after localized therapy with either surgery or radiation.